Literature DB >> 8422459

Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes.

W H Dokter1, M T Esselink, M R Halie, E Vellenga.   

Abstract

We studied the effect of interleukin-4 (IL-4) on the lipopolysaccharide (LPS) induction of two immediate early genes c-fos and c-jun. These genes encode proteins that form the dimeric complex activator protein-1 (AP-1), which is active as a transcriptional factor. Maximal accumulation of either c-fos and c-jun messenger RNA (mRNA) occurred 30 minutes after LPS addition. When cells were treated with IL-4 for 5 hours before LPS activation, both the c-fos and the c-jun mRNA expression was decreased. The inhibition of c-fos and c-jun expression by IL-4 in LPS-treated cells was shown to be due to a lower transcription rate of the c-fos and c-jun genes. IL-4 did not affect the stability of the c-fos and c-jun transcripts. Finally, using electrophoretic mobility shift assays, evidence was obtained that IL-4 inhibits LPS-induced expression of AP-1 protein. These data indicate that IL-4 suppresses the induction of transcription factors in human activated monocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422459

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  MUTZ-3, a monocytic model cell line for interleukin-4 and lipopolysaccharide studies.

Authors:  H Quentmeier; A Duschl; Z B Hu; B Schnarr; M Zaborski; H G Drexler
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells.

Authors:  Alejandro Vazquez-Tello; Rabih Halwani; Qutayba Hamid; Saleh Al-Muhsen
Journal:  J Clin Immunol       Date:  2012-11-16       Impact factor: 8.317

3.  Molecular Mechanisms Underlying the Regulation of the MFG-E8 Gene Promoter Activity in Physiological and Inflammatory Conditions.

Authors:  Xiao Wang; Heng-Fu Bu; Shirley X L Liu; Isabelle G De Plaen; Xiao-Di Tan
Journal:  J Cell Biochem       Date:  2015-09       Impact factor: 4.429

4.  Interleukin-4 as a bone regulatory factor: effects on murine osteoblast-like cells.

Authors:  J A Riancho; J González-Marcías; J A Amado; J M Olmos; J L Fernández-Luna
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

5.  IL-4 inhibition of IL-1 induced Matrix metalloproteinase-3 (MMP-3) expression in human fibroblasts involves decreased AP-1 activation via negative crosstalk involving of Jun N-terminal kinase (JNK).

Authors:  Mariah Chambers; Garrett Kirkpatrick; Michel Evans; Grzegorz Gorski; Sara Foster; Ruth C Borghaei
Journal:  Exp Cell Res       Date:  2013-04-19       Impact factor: 3.905

6.  Interleukin-4 suppresses IL-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts.

Authors:  Kosunique Jenkins; Masoud Javadi; Ruth Carter Borghaei
Journal:  J Periodontol       Date:  2004-02       Impact factor: 6.993

7.  G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis.

Authors:  W H Dokter; A J Dijkstra; S B Koopmans; A B Mulder; B K Stulp; M R Halie; W Keck; E Vellenga
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

8.  Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages.

Authors:  J Hambleton; S L Weinstein; L Lem; A L DeFranco
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

9.  Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

Authors:  S Withoff; E G de Vries; W N Keith; E F Nienhuis; W T van der Graaf; D R Uges; N H Mulder
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.